June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Influence of OCT-examination during ranibizumab treatment of AMD patients in a real-life setting (OCEAN study)
Author Affiliations & Notes
  • Frederic Gunnemann
    Augenärzte am St. Franziskus-Hospital Münster, Münster, Germany
  • Jessica Voegeler
    Novartis Pharma GmbH, Novartis Pharma GmbH, Germany
  • Steffen Schmitz-Valckenberg
    Universitätsaugenklinik Bonn, Bonn, Germany
  • Georg Spital
    Augenärzte am St. Franziskus-Hospital Münster, Münster, Germany
  • Sandra Liakopoulos
    Universitätsaugenklinik Köln, Köln, Germany
  • Focke Ziemssen
    Universitätsaugenklinik Tübingen, Tübingen, Germany
  • Footnotes
    Commercial Relationships   Frederic Gunnemann, None; Jessica Voegeler, Novartis (E); Steffen Schmitz-Valckenberg, Alcon (C), Alcon (F), Allergan (F), Allergan (R), Bayer (F), Bayer (R), Carl Zeiss MediTec (F), Formycon (F), Genentech/Roche (C), Genentech/Roche (F), Genentech/Roche (R), Heidelberg Engineering (F), Heidelberg Engineering (R), Novartis (C), Novartis (F), Optos (F); Georg Spital, Allergan (R), Bayer (R), Heidelberg engineering (R), Novartis (F), Novartis (R), Pfizer (R); Sandra Liakopoulos, Allergan (R), Bayer (R), Heidelberg Engineering (R), Novartis (R), Novartis (C); Focke Ziemssen, Alcon (R), Alimera (C), Allergan (C), Allergan (R), Bayer Healthcare (C), Bayer Healthcare (R), Biogen (R), Boehringer-Ingelheim (C), Novartis (C), Novartis (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frederic Gunnemann, Jessica Voegeler, Steffen Schmitz-Valckenberg, Georg Spital, Sandra Liakopoulos, Focke Ziemssen; Influence of OCT-examination during ranibizumab treatment of AMD patients in a real-life setting (OCEAN study). Invest. Ophthalmol. Vis. Sci. 2017;58(8):412.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Randomized controlled trials have proven the beneficial effect of vascular endothelial growth factor (VEGF) inhibition with ranibizumab in neovascular age-related macular degeneration (nAMD). The non-interventional, prospective OCEAN trial (NCT02194803) was initiated to evaluate ranibizumab treatment patterns in real-life conditions and to allow for a better understanding of challenges. The study evaluated the impact and use of optical coherence tomography (OCT) imaging, the key monitoring tool to guide retreatment in nAMD, which was newly implemented in local guidelines at the beginning of the observational period.

Methods : 5.779 patients are observed in a prospective manner over 24 months. The 12-month interim-analysis evaluated the number of visits, visual acuity, number of injections, the use of diagnostic tools and adverse events of 3.630 patients diagnosed with nAMD (61% female/39% male) with an average age of 77.9 years.

Results : The mean baseline BCVA was 52.0 ETDRS letters. During the first year, patients received an average of 4.5 injections and gained 3.8 respectively 4.2 letters (by injecting ophthalmologists) after 12 months (55.8 ± 23.4 ETDRS letter). 37.9% of patients gained ≥ 5 letters, while 21.1% even gained ≥ 15 letters.
The average time between the first visual acuity assessment and the first ranibizumab treatment was 22.4 days. A subgroup of patients treated with a delay of less than 14 days showed notably higher BCVA gains.
Patients underwent 9.5 BCVA assessments and 4.0 OCT examinations. When OCT imaging was performed at ≥ 4 visits, a higher number of patients achieved ≥ 10 letters (31.1%) compared with patients receiving only one or none OCTs (23.1%). The proportion of patients discontinuing the trial does not show any correlation to patient’s baseline VA. No new safety signals were identified.
An update of 24-month data will be presented.

Conclusions : This interim analysis of the non-interventional OCEAN trial shows a beneficial effect of ranibizumab after 12 months for nAMD patients when observed in a real-life setting. The presented data implies that there might be an association of improvement of VA and number of OCT-examinations. Our data show that better VA gain can be achieved with a higher number of visits using OCT scans for (re-)treatment decisions in a real-life setting.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.